Related Experiment Video
Updated: Aug 26, 2025
Surgical Retrieval, Isolation and In vitro Expansion of Human Anterior Cruciate Ligament-derived Cells for Tissue Engineering Applications
Published on: April 30, 2014
Thicker polyethylene inserts (≥ 13 mm) increase the risk for early failure after primary cruciate-retaining total
Anni Rajamäki1, Mika Niemeläinen2, Mika Junnila2
1Coxa Hospital for Joint Replacement, Niveltie 4, 33520, Tampere, Finland. anni.rajamaki@tuni.fi.
Purpose:
This study investigates whether thicker (PE) inserts lead to a greater risk for revision after TKA. The differences between the TKA designs of three manufacturers (NexGen, PFC Sigma, Triathlon) are also compared.
Methods:
A total of 7643 primary TKA surgeries were included. PE inserts were divided into two groups-"thick PE inserts" with a thickness of 13 mm (mm) or more and "standard PE inserts" with a thickness of less than 13 mm. Three cruciate-retaining (CR) TKA designs (NexGen, PFC Sigma, Triathlon) were included in the study. The differences in failure rates between groups were investigated using Kaplan-Meier survival curves and Cox regression model with hazard ratios (HR). Failure rates were investigated short-term (< 2 years) and long-term (the whole follow-up period). The TKA designs were analysed both together and separately.
Results:
During the whole follow-up period, there were 184 (2.4%) aseptic revisions. The thick PE insert group showed an increased risk for revision compared to the standard PE insert group in both short-term (< 2 years; HR 2.0, CI 1.3 to 3.2) and long term (> 2 years; HR 1.6, CI 1.1 to 2.3) follow-up. The highest revision rate was observed in patients who received the Triathlon TKA with a thicker PE insert (HR 2.6, CI 1.2 to 5.7).
Conclusion:
The results indicate that thicker PE inserts are associated with increased risk for revision in primary TKA. Further research is required to ascertain whether more conformed PE inserts or constrained knee designs instead of thick CR inserts will ultimately lead to better clinical outcomes.
Level Of Evidence:
III.
